NATICK, Mass., June 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced that the U.S. District Court in Delaware issued a ruling upholding a July 2005 jury verdict in a patent case against Johnson & Johnson (J&J) (NYSE: JNJ). The ruling denies J&J's motion to overturn the verdict, in which the jury had found that J&J's Cypher® stent product infringed a Boston Scientific drug coating patent. The jury had also found the patent to be valid.
"We are very pleased that the Court has upheld the jury's verdict in favor of Boston Scientific," said Paul LaViolette, Boston Scientific Chief Operating Officer. "This ruling reaffirms the strength and innovation of our drug-eluting stent technologies."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Charles Rudnick 508-650-8660 Media Relations Boston Scientific Corporation
SOURCE: Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Charles
Rudnick, Media Relations, +1-508-650-8660, both of Boston Scientific
Web site: http://www.bostonscientific.com/